

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Antibody-Drug Conjugates for Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Presented data from the Phase III DESTINY-Breast11 study comparing trastuzumab deruxtecan (T-DXd) followed by paclitaxel/trastuzumab/ pertuzumab (THP) before surgery to standard neoadjuvant therapy for high-risk HER2-positive localized breast cancer reported which of the following efficacy outcomes?
 - a. A numerical but nonsignificant improvement in pathologic complete response (pCR) with T-DXd followed by THP
 - b. A statistically significant improvement in pCR with T-DXd followed by THP**
 - c. A numerical but nonsignificant improvement in overall survival (OS) with T-DXd followed by THP
 - d. A statistically significant improvement in OS with T-DXd followed by THP

2. Recently presented data from the Phase III TROPION-Breast02 study suggest that datopotamab deruxtecan (Dato-DXd) as a component of first-line therapy improves OS and progression-free survival (PFS) for patients with metastatic triple-negative breast cancer in which of the following settings?
 - a. In combination with durvalumab for PD-L1-positive disease
 - b. As monotherapy for patients ineligible for treatment with a PD-L1 inhibitor**
 - c. Both in combination with durvalumab for PD-L1-positive disease and as monotherapy for patients for whom immunotherapy is not an option
 - d. None of the above

3. How did the Phase III ASCENT-03 and TROPION-Breast02 trials approach crossover among patients in the control arm who experienced disease progression on chemotherapy?
 - a. Both the ASCENT-03 and TROPION-Breast02 trials allowed crossover
 - b. Neither the ASCENT-03 trial nor the TROPION-Breast02 trial allowed crossover
 - c. The ASCENT-03 trial allowed crossover, but the TROPION-Breast02 trial did not**
 - d. The TROPION-Breast02 trial allowed crossover, but the ASCENT-03 trial did not

4. Which of the following agents is a TROP2-directed antibody-drug conjugate?
 - a. Dato-DXd
 - b. Mirvetuximab soravtansine
 - c. Sacituzumab govitecan
 - d. T-DXd
 - e. Both a and c**
 - f. Both b and d

5. The Phase III OptiTROP-Breast02 study of sacituzumab tirumotecan versus investigator's choice of chemotherapy for patients with hormone-receptor-positive, HER2-negative metastatic breast cancer who experienced disease progression on up to 4 lines of chemotherapy demonstrated which of the following outcomes?
 - a. A statistically significant improvement in PFS with sacituzumab tirumotecan**
 - b. A statistically significant improvement in PFS and OS with sacituzumab tirumotecan
 - c. A numerical trend toward improvement in PFS with sacituzumab tirumotecan
 - d. A numerical trend toward improvement in PFS and OS with sacituzumab tirumotecan